[Porphyria cutanea tarda--new views on its pathogenesis and therapy].
Literature data and the results of our studies on the prevalence of the HCV infection markers in patients with porphyria cutanea tarda (PCT) are presented. We also present new views on the PCT pathogenesis in some cases, therapy of the cutaneous changes, and the use of interferon in the patients as a prevention of the hepatocellular carcinoma.
Falkiewicz
B
B
III Kliniki Chorób Wewnetrzynch Akademii Medycznej w Gdańsku.
Dabrowska
E
E
Jabłońska-Kaszewska
I
I
D015415:Biomarkers / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000517:prevention & control; D017119:Porphyria Cutanea Tarda / Q000209:etiology* / Q000628:therapy*
D015415:Biomarkers; D007372:Interferons